The State of Peptide Evidence 2026
We indexed 1,095 unique peer-reviewed citations across 65 of the 70 peptides we track. The headline: the most popular peptides are backed mostly by reviews and preclinical (animal and lab) research, not human trials. Fewer than 1 in 5 graded peptides reach strong, FDA-grade human evidence, and only about 21% of the indexed literature is clinical-trial or meta-analysis grade.
How strong is the evidence?
We hand-assigned an evidence grade to 52 peptides — the subset for which we have enough curated literature to judge fairly. A grade of strong means an FDA-approved indication or large randomized controlled trials in humans. Most peptides land in the middle: promising but thinly evidenced.
n = 52 peptides with hand-assigned grades. Percentages rounded.
Only 10 of 52 graded peptides (19%) reach strong human evidence. The other 81% sit at moderate or weaker grades — a reminder that popularity and evidence are not the same thing.
Reviews and preclinical work dominate
Classifying all 1,220 indexed study records by PubMed publication type shows where the literature actually concentrates. Reviews (which summarize other work rather than generate new human data) and preclinical animal or lab studies together make up more than three-quarters of the corpus.
n = 1,220 indexed records. 2 additional records were flagged as retracted and excluded from the analysis (see integrity, below).
The human-evidence gap
If we count only the study types that generate or synthesize human clinical data — clinical trials and meta-analyses — the picture narrows sharply.
The remaining ~79% is reviews and preclinical research.
This gap is the single most important context for anyone reading peptide claims online. A compound can have dozens of citations and still rest almost entirely on animal models and narrative reviews.
Research is accelerating
Indexed studies per publication year show a clear upward trend. Output in 2025 was the highest in our window, roughly 58% above 2020.
Indexed studies by publication year. 2026 is partial and omitted from the trend.
Coverage & integrity
Coverage is uneven. Of the 70 peptides we track, 65 have at least one indexed peer-reviewed study — but 5 have no indexed peer-reviewed research at all. The most-studied compounds (for example BPC-157, TB-500, and GHK-Cu) hit our index’s per-peptide cap, while many others rest on only a handful of studies. We treat this as a measure of breadth of coverage, not a ranking of total research volume — see the methodology caveat below.
Detecting and removing 2 retracted papers matters: retracted findings routinely continue to circulate in supplement marketing. Excluding them keeps the corpus honest.
How we built the corpus
- Source. We indexed peer-reviewed citations from PubMed for each of the 70 peptides we track, capturing journal, publication year, and PubMed publication type. Data is current as of 2026-03-25.
- Scale. The result is 1,095 unique citations and 1,220 total indexed study records across 65 peptides.
- Important cap (read this). Our index captures up to roughly 24 studies per peptide. It is a curated, representative corpus — not an exhaustive count of all published literature. This is why we do not publish a “most-researched peptide” leaderboard: heavily studied compounds hit the cap and would be indistinguishable from one another.
- Evidence grades. Grades (strong / moderate / anecdotal) were hand-assigned for 52 peptides for which we had enough curated literature to judge. “Strong” requires an FDA-approved indication or large RCTs; grading is editorial and open to revision.
- Integrity. 2 retracted papers were detected and excluded from the analyzed corpus.
- Rounding. Percentages are rounded to whole numbers and may not sum to exactly 100%.
Cite this report
This study is free to cite and link. A suggested citation: